Moderna (NASDAQ:MRNA) Stock Price Up 5.8% Following Strong Earnings

Shares of Moderna, Inc. (NASDAQ:MRNA) traded up 5.8% during trading on Monday after the company announced better than expected quarterly earnings. The company traded as high as $280.80 and last traded at $269.00. 12,298,800 shares were traded during mid-day trading, a decline of 3% from the average session volume of 12,650,313 shares. The stock had previously closed at $254.19.

The company reported $0.38 earnings per share for the quarter, topping the consensus estimate of ($1.10) by $1.48. The business had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $890.25 million. Moderna had a negative return on equity of 25.79% and a negative net margin of 110.46%. The firm’s revenue for the quarter was up 29.2% compared to the same quarter last year. During the same period last year, the firm posted ($0.51) EPS.

Key Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna raised its 2026 revenue-growth outlook to 15%–25%, citing respiratory-vaccine gains and lower costs. The upbeat outlook follows a quarterly earnings and revenue beat, strengthening the case that its business is performing better than expected. Moderna Q3 Earnings Call Highlights Raised Outlook and Oncology
• Positive Sentiment: Moderna’s personalized cancer therapy intismeran reduced the risk of melanoma recurrence or death by 42% in Phase 3 data. The company is targeting an FDA filing by the end of 2026, which could set up a regulatory decision in 2027; approval is not assured. Moderna: 3 Key Takeaways for Long-Term Investors
• Negative Sentiment: Valuation remains a concern: Goldman Sachs raised its price target to $195 but kept a neutral rating, while another fair-value estimate increased to $145.42. Both figures are substantially below the stock’s recent trading level, suggesting analysts see downside risk if expectations are not met. Goldman Sachs price-target update

Wall Street Analysts Forecast Growth

MRNA has been the subject of a number of recent research reports. CLSA raised shares of Moderna to an “outperform” rating in a research report on Friday, August 28th. Morgan Stanley increased their target price on shares of Moderna from $89.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 7th. TD Cowen reiterated a “buy” rating on shares of Moderna in a research note on Wednesday, October 21st. Jefferies Financial Group reiterated a “hold” rating and issued a $150.00 price target (up from $60.00) on shares of Moderna in a research note on Wednesday, August 19th. Finally, Citigroup reissued a “sell” rating on shares of Moderna in a research report on Friday, October 23rd. Six investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $113.75.

Insider Buying and Selling at Moderna

In other news, President Stephen Hoge sold 40,294 shares of the company’s stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $144.13, for a total transaction of $5,807,574.22. Following the completion of the sale, the president owned 1,525,858 shares of the company’s stock, valued at approximately $219,921,913.54. This represents a 2.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James M. Mock sold 34,836 shares of the stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the sale, the chief financial officer owned 59,375 shares in the company, valued at $7,985,343.75. This represents a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 197,251 shares of company stock valued at $33,875,904 in the last ninety days. 10.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Moderna

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new position in shares of Moderna in the 2nd quarter valued at $2,142,877,000. Theleme Partners LLP bought a new stake in shares of Moderna during the 2nd quarter worth $564,272,000. Wellington Management Group LLP lifted its position in shares of Moderna by 4.4% during the 2nd quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company’s stock worth $172,384,000 after buying an additional 103,977 shares during the last quarter. First Trust Advisors LP lifted its position in shares of Moderna by 59.3% during the 1st quarter. First Trust Advisors LP now owns 2,392,693 shares of the company’s stock worth $121,549,000 after buying an additional 891,072 shares during the last quarter. Finally, Merck & Co. Inc. acquired a new stake in Moderna in the second quarter valued at about $161,642,545. 75.33% of the stock is currently owned by institutional investors.

Moderna Stock Up 5.8%

The company has a quick ratio of 3.47, a current ratio of 3.62 and a debt-to-equity ratio of 0.52. The firm has a 50 day moving average of $191.85 and a two-hundred day moving average of $91.51. The firm has a market capitalization of $107.39 billion, a price-to-earnings ratio of -37.89 and a beta of 1.16.

About Moderna

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease.

The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases.

Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.